Phenoxazine Acetamides for Ferroptosis Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulated ferroptosis is implicated in diseases such as neuropathy, ischemia reperfusion injury, acute kidney failure, and cancer, with existing treatments lacking effective modulators or inhibitors.
Innovation Solution
Development of phenoxazine acetamide compounds that modulate or inhibit ferroptosis activity, which can be administered as pharmaceutical compositions to treat these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for ferroptosis-related diseases, then current standard therapies can be applied, but effective modulators or inhibitors of ferroptosis are lacking
Solution Approach 1:
The patent modifies the chemical structure of phenoxazine compounds by changing parameters such as substituting hydrogen atoms at specific positions (R1-R8) with various functional groups (halide, OH, NH2, alkyl, F-substituted alkyl), thereby creating a series of compounds with different ferroptosis inhibitory activities to address the lack of effective modulators
Solution Approach 2:
The patent combines the phenoxazine core structure with acetamide side chains and various substituents to create composite molecular structures (formula I compounds) that exhibit enhanced ferroptosis inhibitory activity, effectively addressing the need for reliable ferroptosis modulation
2Reliability
If phenoxazine acetamide compounds are developed as ferroptosis inhibitors, then therapeutic efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct segments: a phenoxazine core scaffold and variable acetamide side chains with specific substituents at defined positions, allowing systematic exploration of structure-activity relationships while maintaining manageable synthesis complexity
Solution Approach 2:
The phenoxazine acetamide scaffold serves as a universal framework that can accommodate multiple substituents (R1-R8) to generate compounds with different activities and properties, enabling a single core structure to address multiple ferroptosis-related diseases
Data Source
AI summary
Provided herein are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.